After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Ultragenyx Pharmaceutical Inc. is $4.45B. A total of 1.55 million shares were traded on the day, compared to an average of 892.70K shares.
In the most recent transaction, Sanders Corazon (Corsee) D. sold 584 shares of RARE for 40.98 per share on Jul 02 ’24. After the transaction, the Director now owns 12,009 company shares. In a previous transaction on Jun 12 ’24, Parschauer Karah Herdman sold 9,806 shares at 45.00 per share. RARE shares that EVP and Chief Legal Officer owns now total 57,981.
Among the insiders who sold shares, Sanders Corazon (Corsee) D. disposed of 1,737 shares on Jun 10 ’24 at a per-share price of $41.10. This resulted in the Director holding 7,248 shares of RARE after the transaction. In another insider transaction, Crombez Eric sold 354 shares at $43.66 per share on May 02 ’24. Company shares held by the EVP and Chief Medical Officer now total 48,431.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, RARE has a high of $54.56 and a low of $31.52.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. RARE’s latest balance sheet shows that the firm has $740.20M in Cash & Short Term Investments as of fiscal 2021. There were $41.97M in debt and $181.37M in liabilities at the time. Its Book Value Per Share was $4.70, while its Total Shareholder’s Equity was $922.56M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RARE is Buy with a score of 4.86.
